However, in our opinion, the targeting of p38 MAPK activity, especially through the use of p38 MAPK inhibitors, such as SB203580, can be considered as a possible pharmacological target for the inhibition of TGF-β1-induced myofibroblast transitions of HBFs during subepithelial fibrosis associated with asthma. This evidence concerns the gene TGFB1 and asthma.